BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, Glória H, Marinho R, Távora I, Ramalho F. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int. 2006;26:680-687. [PMID: 16842324 DOI: 10.1111/j.1478-3231.2006.001285.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Chou YC, Lao IH, Hsieh PL, Su YY, Mak CW, Sun DP, Sheu MJ, Kuo HT, Chen TJ, Ho CH, Kuo YT. Gadoxetic acid-enhanced magnetic resonance imaging can predict the pathologic stage of solitary hepatocellular carcinoma. World J Gastroenterol 2019; 25(21): 2636-2649 [PMID: 31210715 DOI: 10.3748/wjg.v25.i21.2636] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Shen WF, Zhong W, Xu F, Kan T, Geng L, Xie F, Sui CJ, Yang JM. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. World J Gastroenterol 2009; 15(47): 5976-5982 [PMID: 20014463 DOI: 10.3748/wjg.15.5976] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 63] [Article Influence: 5.6] [Reference Citation Analysis]
3 Liberati S, Morelli MB, Amantini C, Farfariello V, Santoni M, Conti A, Nabissi M, Cascinu S, Santoni G. Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor Progression. Cells 2014;3:112-28. [PMID: 24709905 DOI: 10.3390/cells3010112] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
4 Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Chiou YY, Huo TI. A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients. Aliment Pharmacol Ther. 2012;36:551-559. [PMID: 22817677 DOI: 10.1111/j.1365-2036.2012.05226.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sun L, Guan YS, Pan WM, Chen GB, Luo ZM, Wei JH, Wu H. Highly metabolic thrombus of the portal vein: 18F fluorodeoxyglucose positron emission tomography/computer tomography demonstration and clinical significance in hepatocellular carcinoma. World J Gastroenterol 2008; 14(8): 1212-1217 [PMID: 18300346 DOI: 10.3748/wjg.14.1212] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
6 Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One 2014;9:e90929. [PMID: 24603710 DOI: 10.1371/journal.pone.0090929] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
7 Hucke F, Sieghart W, Schöniger-Hekele M, Peck-Radosavljevic M, Müller C. Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? Wien Klin Wochenschr. 2011;123:542-551. [PMID: 21800047 DOI: 10.1007/s00508-011-0033-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
8 Huo TI, Huang YH, Hsia CY, Su CW, Lin HC, Hsu CY, Lee PC, Lui WY, Loong CC, Chiang JH, Chiou YY, Lee SD. Characteristics and outcome of patients with dual hepatitis B and C-associated hepatocellular carcinoma: are they different from patients with single virus infection? Liver Int 2009;29:767-73. [PMID: 19018974 DOI: 10.1111/j.1478-3231.2008.01908.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
9 Choi HJ, Cho BC, Sohn JH, Shin SJ, Kim SH, Kim JH, Yoo NC. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol. 2009;91:307-313. [PMID: 18949445 DOI: 10.1007/s11060-008-9713-3] [Cited by in Crossref: 81] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
10 Guiu B, Colin C, Cercueil J, Loffroy R, Guiu S, Ferrant E, Jouve J, Bonnetain F, Boulin M, Ghiringhelli F, Minello A, Hillon P, Bedenne L, Krause D, Chauffert B. Pilot Study of Transarterial Chemoembolization With Pirarubicin and Amiodarone for Unresectable Hepatocellular Carcinoma. American Journal of Clinical Oncology 2009;32:238-44. [DOI: 10.1097/coc.0b013e3181845529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
11 Ni FB, Lin Z, Fan XH, Shi KQ, Ao JY, Wang XD, Chen RC. A novel genomic-clinicopathologic nomogram to improve prognosis prediction of hepatocellular carcinoma. Clin Chim Acta 2020;504:88-97. [PMID: 32032609 DOI: 10.1016/j.cca.2020.02.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Yoneda N, Matsui O, Kobayashi S, Kitao A, Kozaka K, Inoue D, Yoshida K, Minami T, Koda W, Gabata T. Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma. Jpn J Radiol. 2019;37:191-208. [PMID: 30712167 DOI: 10.1007/s11604-019-00817-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
13 Huo T, Lee S. Role of the model for end-stage liver disease and serum ?-fetoprotein as prognostic predictors for hepatocellular carcinoma. Liver Int 2006;26:1300-1. [DOI: 10.1111/j.1478-3231.2006.01379.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502-510. [PMID: 19141028 DOI: 10.1111/j.1478-3231.2008.01957.x] [Cited by in Crossref: 199] [Cited by in F6Publishing: 200] [Article Influence: 14.2] [Reference Citation Analysis]
15 Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, Zou L, Li ZH, Ye JZ, Li LQ. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. BMC Cancer 2017;17:645. [PMID: 28899349 DOI: 10.1186/s12885-017-3545-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
16 Aljumah AA, Kuriry H, AlZunaitan M, Al Ghobain M, Al Muaikeel M, Al Olayan A, Azzumeea F, Almutairi B, AlAlwan A, AlGhamdi H. Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience. Gastroenterol Res Pract 2016;2016:1989045. [PMID: 27525001 DOI: 10.1155/2016/1989045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
17 Hiotis SP, Rahbari NN, Villanueva GA, Klegar E, Luan W, Wang Q, Yee HT. Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC Gastroenterol. 2012;12:64. [PMID: 22681852 DOI: 10.1186/1471-230x-12-64] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
18 Zhang L, Huang Y, Lian M, Fan Z, Tian Y, Wang Y, Kang H, Liu S, Liu S, Li T, Shan Z. Metabolic profiling of hepatitis B virus-related hepatocellular carcinoma with diverse differentiation grades. Oncol Lett 2017;13:1204-10. [PMID: 28454235 DOI: 10.3892/ol.2017.5596] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
19 Huo TI, Hsu CY, Huang YH, Su CW, Lin HC, Lee RC, Chiou YY, Chiang JH, Lee PC, Lee SD. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. BMC Gastroenterol 2010;10:146. [PMID: 21194431 DOI: 10.1186/1471-230X-10-146] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
20 Eun HS, Kim MJ, Kim HJ, Ko KH, Moon HS, Lee ES, Kim SH, Lee HY, Lee BS. The retrospective cohort study for survival rate in patients with advanced hepatocellular carcinoma receiving radiotherapy or palliative care. Korean J Hepatol 2011;17:189-98. [PMID: 22102385 DOI: 10.3350/kjhep.2011.17.3.189] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
21 Cho ES, Choi JY. MRI features of hepatocellular carcinoma related to biologic behavior. Korean J Radiol. 2015;16:449-464. [PMID: 25995679 DOI: 10.3348/kjr.2015.16.3.449] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
22 Vogl TJ, Nour-Eldin NE, Emad-Eldin S, Naguib NN, Trojan J, Ackermann H, Abdelaziz O. Portal vein thrombosis and arterioportal shunts: Effects on tumor response after chemoembolization of hepatocellular carcinoma. World J Gastroenterol 2011; 17(10): 1267-1275 [PMID: 21455325 DOI: 10.3748/wjg.v17.i10.1267] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
23 Tang JY, Ohri N, Kabarriti R, Aparo S, Chuy J, Goel S, Schwartz JM, Kinkhabwala M, Kaubisch A, Guha C. Model for End-Stage Liver Disease and Sodium Velocity Predicts Overall Survival in Nonmetastatic Hepatocellular Carcinoma Patients. Can J Gastroenterol Hepatol 2018;2018:5681979. [PMID: 30533403 DOI: 10.1155/2018/5681979] [Reference Citation Analysis]
24 Kim JH, Park JW, Koh DW, Lee WJ, Kim CM. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma. Liver Int. 2009;29:203-207. [PMID: 18662281 DOI: 10.1111/j.1478-3231.2008.01828.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
25 Sieghart W, Fellner S, Reiberger T, Ulbrich G, Ferlitsch A, Wacheck V, Peck-radosavljevic M. Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma. Digestive and Liver Disease 2009;41:902-6. [DOI: 10.1016/j.dld.2009.04.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
26 Huo TI, Lin HC, Hsia CY, Huang YH, Wu JC, Chiang JH, Chiou YY, Lui WY, Lee PC, Lee SD. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig Liver Dis. 2008;40:882-889. [PMID: 18339595 DOI: 10.1016/j.dld.2008.01.015] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
27 Post SE, Sodhi NK, Peng CH, Wan K, Pollack HJ. A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective. Health Aff (Millwood) 2011;30:340-8. [PMID: 21289356 DOI: 10.1377/hlthaff.2008.0905] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
28 Feng M, Zhang M, Liu Y, Jiang N, Meng Q, Wang J, Yao Z, Gan W, Dai H. Texture analysis of MR images to identify the differentiated degree in hepatocellular carcinoma: a retrospective study. BMC Cancer 2020;20:611. [PMID: 32605628 DOI: 10.1186/s12885-020-07094-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Liu G, Xie C, Sun F, Xu X, Yang Y, Zhang T, Deng Y, Wang D, Huang Z, Yang L, Huang S, Wang Q, Liu G, Zhong D, Miao X. Clinical significance of transient receptor potential vanilloid 2 expression in human hepatocellular carcinoma. Cancer Genetics and Cytogenetics 2010;197:54-9. [DOI: 10.1016/j.cancergencyto.2009.08.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
30 Chen T, Chang T, Huang P, Tsai M, Lin L, Liu C, Ho K, Siauw C, Chao P, Tung J. Management and patient survival in hepatocellular carcinoma: Does the physician's level of experience matter? Journal of Gastroenterology and Hepatology 2008;23:e179-88. [DOI: 10.1111/j.1440-1746.2008.05341.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
31 Zheng H, Xu C, Wang X, Li J, Zhao X, Qi J, Feng Y, Zhu Q. Microwave ablation shows similar survival outcomes compared with surgical resection for hepatocellular carcinoma between 3 and 5 cm. Int J Hyperthermia 2020;37:1345-53. [PMID: 33289415 DOI: 10.1080/02656736.2020.1849825] [Reference Citation Analysis]
32 Huang K, Dong Z, Cai H, Huang M, Peng Z, Xu L, Jia Y, Song C, Li ZP, Feng ST. Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation. BMC Cancer 2019;19:364. [PMID: 30999947 DOI: 10.1186/s12885-019-5574-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
33 Baek YH, Kim KT, Lee SW, Jeong JS, Park BH, Nam KJ, Cho JH, Kim YH, Roh YH, Lee HS, Choi YM, Han SY. Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. World J Gastroenterol 2012; 18(26): 3426-3434 [PMID: 22807613 DOI: 10.3748/wjg.v18.i26.3426] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
34 Woo SM, Park JW, Lee WJ, Kim CM. Clinical and virological responses to clevudine therapy of hepatocelluar carcinoma patients with chronic hepatitis B. Gut Liver 2011;5:82-7. [PMID: 21461078 DOI: 10.5009/gnl.2011.5.1.82] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
35 Zhou L, Rui JA, Ye DX, Wang SB, Chen SG, Qu Q. Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection. World J Surg. 2008;32:1748-1756. [PMID: 18493820 DOI: 10.1007/s00268-008-9615-8] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 4.5] [Reference Citation Analysis]
36 Qi X, Wang D, Su C, Li H, Guo X. Hepatic resection vs transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Oncotarget. 2015;6:18715-18733. [PMID: 26243835 DOI: 10.18632/oncotarget.4134] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
37 Brown DB, Chapman WC, Cook RD, Kerr JR, Gould JE, Pilgram TK, Darcy MD. Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over 15 years at a single center. AJR Am J Roentgenol. 2008;190:608-615. [PMID: 18287429 DOI: 10.2214/ajr.07.2879] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
38 Fernández-Ruiz M, Guerra-Vales JM, Castelbón-Fernández FJ, Llenas-García J, Caurcel-Díaz L, Colina-Ruizdelgado F. Multiple primary malignancies in Spanish patients with hepatocellular carcinoma: analysis of a hospital-based tumor registry. J Gastroenterol Hepatol 2009;24:1424-30. [PMID: 19486257 DOI: 10.1111/j.1440-1746.2009.05793.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
39 Marelli L, Shusang V, Buscombe JR, Cholongitas E, Stigliano R, Davies N, Tibballs J, Patch D, Meyer T, Burroughs AK. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. J Nucl Med 2009;50:871-7. [PMID: 19443599 DOI: 10.2967/jnumed.108.060558] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]